CN103249415B - 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 - Google Patents

包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 Download PDF

Info

Publication number
CN103249415B
CN103249415B CN201180058951.9A CN201180058951A CN103249415B CN 103249415 B CN103249415 B CN 103249415B CN 201180058951 A CN201180058951 A CN 201180058951A CN 103249415 B CN103249415 B CN 103249415B
Authority
CN
China
Prior art keywords
valsartan
lercanidipine hydrochloride
lercanidipine
tablet
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180058951.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103249415A (zh
Inventor
丁荣识
朴秀娥
金利宣
金成�
金成一
全宰贤
金烔煃
金由璘
朴熙东
朴圣在
李承学
金周铉
郑珉英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103249415(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Publication of CN103249415A publication Critical patent/CN103249415A/zh
Application granted granted Critical
Publication of CN103249415B publication Critical patent/CN103249415B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180058951.9A 2010-12-09 2011-12-07 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 Active CN103249415B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
KR10-2010-0125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (2)

Publication Number Publication Date
CN103249415A CN103249415A (zh) 2013-08-14
CN103249415B true CN103249415B (zh) 2017-12-12

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180058951.9A Active CN103249415B (zh) 2010-12-09 2011-12-07 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法

Country Status (17)

Country Link
EP (1) EP2648730A4 (pt)
KR (1) KR101414814B1 (pt)
CN (1) CN103249415B (pt)
AR (1) AR084195A1 (pt)
AU (1) AU2011339150B2 (pt)
BR (1) BR112013013415A2 (pt)
CL (1) CL2013001626A1 (pt)
CO (1) CO6721030A2 (pt)
DO (1) DOP2013000115A (pt)
EA (1) EA201390844A1 (pt)
IL (1) IL226449A0 (pt)
MX (1) MX2013005716A (pt)
PE (1) PE20140699A1 (pt)
SG (1) SG190326A1 (pt)
UA (1) UA108277C2 (pt)
UY (1) UY33772A (pt)
WO (1) WO2012077968A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
BR112015022103A2 (pt) * 2013-03-12 2017-07-18 Lg Life Sciences Ltd composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
JP5110697B2 (ja) * 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
UY33772A (es) 2012-07-31
CN103249415A (zh) 2013-08-14
KR20120089787A (ko) 2012-08-13
SG190326A1 (en) 2013-06-28
EP2648730A2 (en) 2013-10-16
AU2011339150B2 (en) 2015-09-10
DOP2013000115A (es) 2014-07-31
AR084195A1 (es) 2013-04-24
PE20140699A1 (es) 2014-06-13
EA201390844A1 (ru) 2013-11-29
CO6721030A2 (es) 2013-07-31
AU2011339150A1 (en) 2013-06-06
WO2012077968A3 (en) 2012-07-26
EP2648730A4 (en) 2014-08-06
KR101414814B1 (ko) 2014-07-21
BR112013013415A2 (pt) 2019-09-24
IL226449A0 (en) 2013-07-31
MX2013005716A (es) 2013-06-12
CL2013001626A1 (es) 2013-10-04
WO2012077968A2 (en) 2012-06-14
UA108277C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
JP5597343B2 (ja) 抗痴呆薬を含有する組成物
US7741374B1 (en) Methods of use of fenofibric acid
US20100047341A1 (en) Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
US20060246003A1 (en) Composition containing anti-dementia drug
CN103751193A (zh) 包含利拉列汀和任选的sglt2抑制剂的药物组合物及其用途
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
KR20070085754A (ko) 안정화된 라미프릴 조성물 및 제조 방법
KR101205633B1 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
KR101515490B1 (ko) 고혈압 및 대사증후군 질환 치료용 약학적 조성물 및 이의 용도
CN108156807A (zh) 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
JP2011507973A (ja) アムロジピンとバルサルタンとの医薬組成物
US20030147957A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
CN101653440B (zh) 含有氨氯地平系列盐和普利类药物的治疗组合物
CN106310278A (zh) 一种含叶酸的多联降压药物组合物
WO2009027786A2 (en) Matrix dosage forms of varenicline
CN101416966B (zh) 一种治疗高血压的药物组合物
EP4079297A1 (en) Pharmaceutical formulation comprising cibenzoline or salt thereof
TWI827828B (zh) 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑
WO2024047208A1 (en) Anticoagulant therapy with an improved dosage regimen
KR20240045205A (ko) 메타돈과 그 이성질체, 에스메타돈 및 레보메타돈과 유도체의 변형 방출 제제
WO2023175573A1 (en) Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
KR20090107961A (ko) 심혈관계 질환 치료용 약제학적 제제
EP3087978A1 (en) Sustained-release pharmaceutical composition containing acebrophylline and hydrophillic sustained-release agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170913

Address after: Seoul, South Kerean

Applicant after: LG Chemical Co., Ltd.

Address before: Seoul, South Kerean

Applicant before: LG Life Sciences Ltd

GR01 Patent grant
GR01 Patent grant